Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase II trial of IMA-901 shows benefit of cyclophosphamide pretreatment

Oct. 4, 2010

NNC-126-0083 is well tolerated in adults and children with growth hormone deficiency

Oct. 4, 2010

Phase I investigation of CombiHIVvac HIV vaccine begins

Oct. 4, 2010

EP-017796 is active against drug-resistant bacteria

Oct. 4, 2010

Cationic peptide NP-339 is active against Candida species

Oct. 4, 2010

CMX-001 is not nephrotoxic in patients with viral infections

Oct. 4, 2010

Chitosan-GP is efficacious in ongoing trial in patients with articular cartilage lesions

Oct. 1, 2010

SAR-707 reveals limitations of acyl-CoA desaturase inhibition in metabolic disorders

Oct. 1, 2010

TransVax reduces cytomegalovirus viremia in phase II trial

Oct. 1, 2010

Phase II data show efficacy of Gilead Sciences' Quad anti-HIV regimen through 48 weeks

Oct. 1, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...